These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25997147)

  • 1. A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation.
    Aboutorabian S; Hakimi J; Boudet F; Montano S; Dookie A; Roque C; Ausar SF; Rahman N; Brookes RH
    Hum Vaccin Immunother; 2015; 11(6):1449-55. PubMed ID: 25997147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
    Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
    Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis vaccine candidate: Characterization of H4-IC31 formulation and H4 antigen conformation.
    Deshmukh SS; Magcalas FW; Kalbfleisch KN; Carpick BW; Kirkitadze MD
    J Pharm Biomed Anal; 2018 Aug; 157():235-243. PubMed ID: 29866391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
    Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
    Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
    van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
    Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
    Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
    Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry: An efficient method for antigenicity measurement and particle characterization on an adjuvanted vaccine candidate H4-IC31 for tuberculosis.
    He L; Su J; Ming M; Bernardo L; Chen T; Gisonni-Lex L; Gajewska B
    J Immunol Methods; 2018 Jan; 452():39-45. PubMed ID: 29056527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro functional assay to measure the biological activity of TB vaccine candidate H4-IC31.
    Ming M; Bernardo L; Williams K; Kolattukudy P; Kapoor N; Chan LG; Pagnon A; Piras F; Su J; Gajewska B; Salha D; Gisonni-Lex L
    Vaccine; 2019 May; 37(22):2960-2966. PubMed ID: 31010716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
    Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
    Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.
    Agger EM; Rosenkrands I; Olsen AW; Hatch G; Williams A; Kritsch C; Lingnau K; von Gabain A; Andersen CS; Korsholm KS; Andersen P
    Vaccine; 2006 Jun; 24(26):5452-60. PubMed ID: 16675077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H1:IC31 vaccination is safe and induces long-lived TNF-α
    Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
    Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
    Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
    N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The two-component adjuvant IC31® boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs.
    Szabo A; Gogolak P; Pazmandi K; Kis-Toth K; Riedl K; Wizel B; Lingnau K; Bacsi A; Rethi B; Rajnavolgyi E
    PLoS One; 2013; 8(2):e55264. PubMed ID: 23405128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells.
    Aichinger MC; Ginzler M; Weghuber J; Zimmermann L; Riedl K; Schütz G; Nagy E; von Gabain A; Schweyen R; Henics T
    Vaccine; 2011 Jan; 29(3):426-36. PubMed ID: 21093498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
    Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
    Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.
    Aagaard C; Hoang TT; Izzo A; Billeskov R; Troudt J; Arnett K; Keyser A; Elvang T; Andersen P; Dietrich J
    PLoS One; 2009 Jun; 4(6):e5930. PubMed ID: 19529771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice.
    Olafsdottir TA; Lingnau K; Nagy E; Jonsdottir I
    Infect Immun; 2012 Jan; 80(1):461-8. PubMed ID: 22025519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
    Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
    Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
    Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
    Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
    van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
    Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.